Clinical trials: First Line Treatment
Chronic Myeloid Leukemia
Nilotinib in PH+, BCR-, ABL+ CML Patients
This study is an open-label, multicentric, phase IIIb study of NILOTINIB administered orally twice daily for 24 months and indefinitely if it is in the interest of the patient.
- Trial name
- CML0811 (NCT01535391)
- Testing
- Nilotinib
- Where
- 34 sites in Italy
- Volunteers
- 109 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Esophageal Squamous Cell Carcinoma
Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma
Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT02677597
- Testing
- Cisplatin Combined With S-1, Cisplatin Combined With Paclitaxel
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Fudan University
Colorectal Cancer
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Patients with metastatic colorectal cancer will be treated with chemotherapy according to investigators choice. In addition to chemotherapy treatment, treatment with bevacizumab will be given concomitantly.
- Trial name
- ACT2 (NCT01229813)
- Testing
- bevacizumab, erlotinib, bevacizumab, low dose capecitabine
- Where
- 12 sites in Denmark, Sweden
- Volunteers
- 233 people
- Sponsor
- Lund University Hospital
First Line Non-Small Cell Lung Cancer
Avelumab in First-line NSCLC (JAVELIN Lung 100)
The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in…
- Trial name
- NCT02576574
- Testing
- Avelumab, Pemetrexed, Paclitaxel
- Where
- 349 sites in United States, Australia and 40 more
- Volunteers
- 1,214 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non-Squamous Non-Small Cell Lung Cancer
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
This open-label, randomized, multicenter study will evaluate the efficacy and safety of bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants with advanced non-squamous NSCLC.
- Trial name
- NCT01351415
- Testing
- Bevacizumab, Docetaxel, Erlotinib
- Where
- 179 sites in United States, Argentina and 16 more
- Volunteers
- 485 people
- Sponsor
- Hoffmann-La Roche
Extensive Stage Lung Small Cell Cancer
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination…
- Trial name
- PrE0510 (NCT07057791)
- Testing
- Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- PrECOG, LLC.
Non-Small Cell Lung Cancer
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous…
- Trial name
- NCT07416474
- Testing
- RC148 plus Carboplatin and Paclitaxel, Tislelizumab plus Carboplatin and Paclitaxel
- Where
- 78 sites in China
- Volunteers
- 574 people
- Sponsor
- RemeGen Co., Ltd.
Acute Myeloid Leukemia
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
This phase I/II clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame of first-line standard chemotherapy in newly diagnosed acute myeloid leukemia…
- Trial name
- MOSAIC (NCT04385290)
- Testing
- MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO
- Where
- 21 sites in Germany
- Volunteers
- 214 people
- Sponsor
- Technische Universität Dresden
Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
This is a single arm, multi-center clinical trial. The goal of this clinical trial is to evaluate the efficacy, safety and biomarkers of Tafolecimab combined with Sintilimab and Chemotherapy as first-line treatment for patients…
- Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
- Trial name
- STAR-SCLC (NCT07061535)
- Testing
- Tafolecimab, Sintilimab (approved), Etoposide
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-Small Cell Lung Cancer
Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC
This is a clinical research study to evaluate if chemotherapy in the experimental arm (E) results in a better outcome compared to patients in the standard of care arm (C).
- Trial name
- NCT00499109
- Testing
- Docetaxel, Vinorelbine, Carboplatin
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 275 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Esophageal Cancer by AJCC V8 Stage
Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
To evaluate the efficacy and safety of patients with advanced esophageal squamous cell carcinoma treated with camrelizumab combined with Apatinib mesylate plus short-course chemotherapy versus standard chemotherapy in first line
- Trial name
- NCT05738434
- Testing
- Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib, Camrelizumab+Chemotherapy→Camrelizumab
- Where
- China
- Volunteers
- 188 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Advanced Lung Carcinoma, Non-small Cell Lung Cancer
Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer
Lung cancer is one of the malignant tumors with high morbidity and mortality. Several PD-1/PD-L1 immune checkpoint inhibitors have been approved for the treatment of advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT04702009
- Testing
- Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
IBI363 + Chemotherapy
Study of IBI363 in Patients with Advanced First-line Gastric Cancer
This is a phase 1b study designed to evaluate the safety, tolerability and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) in first-line treatment of unresectable advanced or metastatic gastric and…
- Trial name
- NCT06610799
- Testing
- IBI363
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xiangdong Cheng
Triple Negative Breast Neoplasms
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
- Trial name
- BEGONIA (NCT03742102)
- Testing
- Durvalumab, Capivasertib, Oleclumab
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 243 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer
This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer. Each cycle of treatment will be 4 weeks in length.
- Trial name
- NCT00251472
- Testing
- Paclitaxel Albumin Nanoparticle for Injectable Suspension
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Veeda Oncology
Non Squamous Non Small Cell Lung Cancer
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The objective of this bridging study is to acquire new drug approval in Korea for camrelizumab (SHR-1210), a drug that has already been approved in China for treatment in patients with histologically or cytologically confirmed…
- Trial name
- NCT05841472
- Testing
- Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
- Where
- 8 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- CrystalGenomics, Inc.
Squamous Cell Carcinoma of the Head and Neck
Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT03855384
- Testing
- TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
- Where
- China
- Volunteers
- 334 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Unresectable/Metastatic Colorectal Cancer
Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
FOLFOXIRI-based regimen is more used as a first-line therapeutic approach for patients diagnosed with unresectable or metastatic colorectal cancer for its superior efficacy.
- Trial name
- NCT06148402
- Testing
- Fruquintinib plus camrelizumab and capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HER2-positive Gastric Cancer, Metastatic Cancer
Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients
The purpose of this retrospective study is to evaluate the efficacy and the safety of trastuzumab + chemotherapies with or without taxanes among HER2-positive advanced gastroesophageal adenocarcinoma patients.
- Conditions
- HER2-positive Gastric Cancer, Metastatic Cancer, Docetaxel, Trastuzumab
- Trial name
- TandHER (NCT04920747)
- Testing
- Taxane
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Breast Cancer
HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy
This observational study will evaluate the efficacy, safety and patient reported quality of life of palliative first-line Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) in patients with HER2-positive advanced…
- Trial name
- NCT01777958
- Where
- Germany
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.